Large fragment pre-s deletion and high viral load independently predict hepatitis B relapse after liver transplantation

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Wu, Ting Jung ^a,b   Chen, Tse Ching ^a   Wang, Frank ^a   Chan, Kun Ming ^a   Soong, Ruey Shyang ^a   Chou, Hong Shiue ^a   Lee, Wei Chen ^a   Yeh, Chau Ting ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; VIRUS DNA; L PROTEIN, HEPATITIS B VIRUS; VIRUS ENVELOPE PROTEIN;

ANTIGEN EXPRESSION; ARTICLE; BASE PAIRING; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; EXPLANT; GENE DELETION; HEPATITIS B; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LARGE FRAGMENT PRE S DELETION; LIVER FAILURE; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PREOPERATIVE EVALUATION; PREOPERATIVE TREATMENT; RECURRENCE RISK; RISK FACTOR; TREATMENT DURATION; VIRUS LOAD; VIRUS MUTATION; DISEASE FREE SURVIVAL; GENETICS; HEPATITIS B VIRUS; IMMUNOHISTOCHEMISTRY; LIVER; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; TREATMENT OUTCOME; VIROLOGY;

DISEASE-FREE SURVIVAL; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER; LIVER TRANSPLANTATION; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; SEQUENCE DELETION; TREATMENT OUTCOME; VIRAL ENVELOPE PROTEINS; VIRAL LOAD;

EID: 84857396008     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0032189     Document Type: Article

References (37)

1. Kao JH, Chen DS, (2002) Global control of hepatitis B virus infection. Lancet Infect Dis 2: 395-403.
2. Chen DS, (1993) From hepatitis to hepatoma: lessons from type B viral hepatitis. Science 262: 369-370.
3. Starzl TE, Marchioro TL, Vonkaulla KN, Hermann G, Brittain RS, et al. (1963) Homotransplantation of the Liver in Humans. Surg Gynecol Obstet 117: 659-676.
4. Lake JR, Wright TL, (1991) Liver transplantation for patients with hepatitis B: what have we learned from our results? Hepatology 13: 796-799.
5. Todo S, Demetris AJ, Van Thiel D, Teperman L, Fung JJ, et al. (1991) Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology 13: 619-626.
6. Tchervenkov JI, Tector AJ, Barkun JS, Sherker A, Forbes CD, et al. (1997) Recurrence-free long-term survival after liver transplantation for hepatitis B using interferon-alpha pretransplant and hepatitis B immune globulin posttransplant. Ann Surg 226: 356-365; discussion 365-358.
7. Shouval D, Samuel D, (2000) Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review. Hepatology 32: 1189-1195.
8. Markowitz JS, Martin P, Conrad AJ, Markmann JF, Seu P, et al. (1998) Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 28: 585-589.
9. Rosenau J, Bahr MJ, Tillmann HL, Trautwein C, Klempnauer J, et al. (2001) Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. J Hepatol 34: 895-902.
10. Marzano A, Salizzoni M, Debernardi-Venon W, Smedile A, Franchello A, et al. (2001) Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 34: 903-910.
11. Angus PW, McCaughan GW, Gane EJ, Crawford DH, Harley H, (2000) Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl 6: 429-433.
12. Han SH, Ofman J, Holt C, King K, Kunder G, et al. (2000) An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl 6: 741-748.
13. Steinmuller T, Seehofer D, Rayes N, Muller AR, Settmacher U, et al. (2002) Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology 35: 1528-1535.
14. Kim WR, Poterucha JJ, Kremers WK, Ishitani MB, Dickson ER, (2004) Outcome of liver transplantation for hepatitis B in the United States. Liver Transpl 10: 968-974.
15. Lok AS, (2002) Prevention of recurrent hepatitis B post-liver transplantation. Liver Transpl 8: S67-73.
16. Angus PW, Patterson SJ, (2008) Liver transplantation for hepatitis B: what is the best hepatitis B immune globulin/antiviral regimen? Liver Transpl 14 (Suppl 2): S15-22.
17. Lake JR, (2008) Do we really need long-term hepatitis B hyperimmune globulin? What are the alternatives? Liver Transpl 14 (Suppl 2): S23-26.
18. Marzano A, Gaia S, Ghisetti V, Carenzi S, Premoli A, et al. (2005) Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. Liver Transpl 11: 402-409.
19. Chun J, Kim W, Kim BG, Lee KL, Suh KS, et al. (2010) High viremia, prolonged Lamivudine therapy and recurrent hepatocellular carcinoma predict posttransplant hepatitis B recurrence. Am J Transplant 10: 1649-1659.
20. Yi NJ, Suh KS, Cho JY, Kwon CH, Lee KW, et al. (2007) Recurrence of hepatitis B is associated with cumulative corticosteroid dose and chemotherapy against hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl 13: 451-458.
21. Faria LC, Gigou M, Roque-Afonso AM, Sebagh M, Roche B, et al. (2008) Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. Gastroenterology 134: 1890-1899; quiz 2155.
22. Saab S, Yeganeh M, Nguyen K, Durazo F, Han S, et al. (2009) Recurrence of hepatocellular carcinoma and hepatitis B reinfection in hepatitis B surface antigen-positive patients after liver transplantation. Liver Transpl 15: 1525-1534.
23. Woo HY, Choi JY, Jang JW, You CR, Bae SH, et al. (2008) Role of long-term lamivudine treatment of hepatitis B virus recurrence after liver transplantation. J Med Virol 80: 1891-1899.
24. Yeh CT, So M, Ng J, Yang HW, Chang ML, et al. (2010) Hepatitis B virus-DNA level and basal core promoter A1762T/G1764A mutation in liver tissue independently predict postoperative survival in hepatocellular carcinoma. Hepatology 52: 1922-1933.
25. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, et al. (1995) Histological grading and staging of chronic hepatitis. J Hepatol 22: 696-699.
26. Fung J, Cheung C, Chan SC, Yuen MF, Chok KS, et al. (2011) Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation. Gastroenterology 141: 1212-1219.
27. Wong SN, Chu CJ, Wai CT, Howell T, Moore C, et al. (2007) Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy. Liver Transpl 13: 374-381.
28. Lenci I, Tisone G, Di Paolo D, Marcuccilli F, Tariciotti L, et al. (2011) Safety of complete and sustained prophylaxis withdrawal in patients liver-transplanted for HBV-related cirrhosis at low risk of HBV recurrence. J Hepatol 55: 587-593.
29. Nath DS, Kalis A, Nelson S, Payne WD, Lake JR, et al. (2006) Hepatitis B prophylaxis post-liver transplant without maintenance hepatitis B immunoglobulin therapy. Clin Transplant 20: 206-210.
30. Chen BF, Liu CJ, Jow GM, Chen PJ, Kao JH, et al. (2006) High prevalence and mapping of pre-S deletion in hepatitis B virus carriers with progressive liver diseases. Gastroenterology 130: 1153-1168.
31. Chen CH, Hung CH, Lee CM, Hu TH, Wang JH, et al. (2007) Pre-S deletion and complex mutations of hepatitis B virus related to advanced liver disease in HBeAg-negative patients. Gastroenterology 133: 1466-1474.
32. Grottola A, Buttafoco P, Del Buono MG, Cremonini C, Colantoni A, et al. (2002) Pretransplantation pre-S2 and S protein heterogeneity predisposes to hepatitis B virus recurrence after liver transplantation. Liver Transpl 8: 443-448.
33. Locarnini S, McMillan J, Bartholomeusz A, (2003) The hepatitis B virus and common mutants. Semin Liver Dis 23: 5-20.
34. Yuen MF, Sablon E, Yuan HJ, Wong DK, Hui CK, et al. (2003) Significance of hepatitis B genotype in acute exacerbation, HBeAg seroconversion, cirrhosis-related complications, and hepatocellular carcinoma. Hepatology 37: 562-567.
35. Gaglio P, Singh S, Degertekin B, Ishitani M, Hussain M, et al. (2008) Impact of the hepatitis B virus genotype on pre- and post-liver transplantation outcomes. Liver Transpl 14: 1420-1427.
36. Lo CM, Cheung CK, Lau GK, Yuen MF, Liu CL, et al. (2005) Significance of hepatitis B virus genotype in liver transplantation for chronic hepatitis B. Am J Transplant 5: 1893-1900.
37. Degertekin B, Han SH, Keeffe EB, Schiff ER, Luketic VA, et al. (2010) Impact of Virologic Breakthrough and HBIG Regimen on Hepatitis B Recurrence After Liver Transplantation. Am J Transplant 10: 1823-1833.